Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Total Liabilities & Equity
Idorsia Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Idorsia Ltd
SIX:IDIA
|
Total Liabilities & Equity
CHf500m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
||
AC Immune SA
NASDAQ:ACIU
|
Total Liabilities & Equity
CHf244.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
||
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Liabilities & Equity
$2.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
Molecular Partners AG
SIX:MOLN
|
Total Liabilities & Equity
CHf170.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
||
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Liabilities & Equity
CHf188.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
||
Kuros Biosciences AG
SIX:KURN
|
Total Liabilities & Equity
CHf77.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
500m
CHF
Based on the financial report for Dec 31, 2023, Idorsia Ltd's Total Liabilities & Equity amounts to 500m CHF.
What is Idorsia Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-19%
Over the last year, the Total Liabilities & Equity growth was -45%. The average annual Total Liabilities & Equity growth rates for Idorsia Ltd have been -30% over the past three years , -19% over the past five years .